Literature DB >> 34643916

Determination of Bioenergetic Parameters in Mycobacterium ulcerans.

Sangeeta Susan Thomas1,2, Kevin Pethe3,4.   

Abstract

The oxidative phosphorylation (OxPhos) pathway has emerged as an attractive pathway for the development of anti-mycobacterial drugs. The OxPhos pathway is essential for ATP resynthesis and maintenance of the electrochemical transmembrane gradient. The bioenergetic parameters of the pathway such as oxygen consumption rate and ATP levels are quantifiable using current technology. Measuring these parameters are useful tools to gauge rapidly the impact of drug candidates on their capacity to inhibit the OxPhos pathway in Mycobacterium ulcerans.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ATP quantitation; Bedaquiline; Buruli ulcer; Mycobacterium tuberculosis; Oxidative phosphorylation; Oxygen consumption rate; Q203; Telacebec

Mesh：

Substances：

Year:  2022        PMID： 34643916     DOI： 10.1007/978-1-0716-1779-3_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  11 in total

1.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

2.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis.

Authors:  Srinivasa P S Rao; Sylvie Alonso; Lucinda Rand; Thomas Dick; Kevin Pethe
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

3.  Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer.

Authors:  Timothy P Stinear; Torsten Seemann; Sacha Pidot; Wafa Frigui; Gilles Reysset; Thierry Garnier; Guillaume Meurice; David Simon; Christiane Bouchier; Laurence Ma; Magali Tichit; Jessica L Porter; Janine Ryan; Paul D R Johnson; John K Davies; Grant A Jenkin; Pamela L C Small; Louis M Jones; Fredj Tekaia; Françoise Laval; Mamadou Daffé; Julian Parkhill; Stewart T Cole
Journal:  Genome Res       Date:  2007-01-08       Impact factor: 9.043

4.  Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection.

Authors:  Nitin P Kalia; Erik J Hasenoehrl; Nurlilah B Ab Rahman; Vanessa H Koh; Michelle L T Ang; Dannah R Sajorda; Kiel Hards; Gerhard Grüber; Sylvie Alonso; Gregory M Cook; Michael Berney; Kevin Pethe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

5.  Diarylquinolines target subunit c of mycobacterial ATP synthase.

Authors:  Anil Koul; Najoua Dendouga; Karen Vergauwen; Brenda Molenberghs; Luc Vranckx; Rudy Willebrords; Zorica Ristic; Holger Lill; Ismet Dorange; Jerome Guillemont; Dirk Bald; Koen Andries
Journal:  Nat Chem Biol       Date:  2007-05-13       Impact factor: 15.040

6.  Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans.

Authors:  Nicole Scherr; Gerd Pluschke; Manoranjan Panda
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 7.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

Review 8.  Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery.

Authors:  Dirk Bald; Cristina Villellas; Ping Lu; Anil Koul
Journal:  mBio       Date:  2017-04-11       Impact factor: 7.867

9.  Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer.

Authors:  Nicole Scherr; Raphael Bieri; Sangeeta S Thomas; Aurélie Chauffour; Nitin Pal Kalia; Paul Schneide; Marie-Thérèse Ruf; Araceli Lamelas; Malathy S S Manimekalai; Gerhard Grüber; Norihisa Ishii; Koichi Suzuki; Marcel Tanner; Garrett C Moraski; Marvin J Miller; Matthias Witschel; Vincent Jarlier; Gerd Pluschke; Kevin Pethe
Journal:  Nat Commun       Date:  2018-12-18       Impact factor: 14.919

10.  Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.

Authors:  Aurélie Chauffour; Jérôme Robert; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier
Journal:  PLoS Negl Trop Dis       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.